Hernia, Inguinal

TUESDAY, Aug. 12, 2024 -- At least 20 million hernia surgeries are performed globally each year, making it one of the most common medical procedures in the world. But does gender matter when it comes to hernia risk? New Australian research says yes: Half of the nearly 436,000 hernia repair procedures performed in adults in that country between 2017 and 2021 were for inguinal (groin) hernias, with men accounting for 89.6% of those operations. And the age-standardized prevalence in men was more than seven times that of women. Inguinal hernias were the most common type of hernia seen in the study. Why are men more susceptible? Researchers say the gender difference is due to higher rates of smoking, heavy exercise, bladder issues, chronic airway disorders, hypertension and heart disease. It’s important that doctors know "those patients who have higher risks of hernia repair, so we can develop health campaigns and policies to improve their quality of life and lower their risks of developing hernias,” study co-author Dr. Marianne Gillam , from the University of South Australia, said in a university news release. A hernia occurs when one of your organs pushes through the muscle or tissue that contains it. This can trigger discomfort and abdominal pain and in severe cases can strangulate the bowel, which requires emergency surgery. In the study, the team turned to data from the Australian Institute of Health & Welfare (AIHW) to crunch the numbers for five different types of hernia operations, identifying what age groups and genders were at highest risk. What did they find? Males had a far higher incidence of inguinal hernias compared to females, with lifetime risks of 27% and 3%, respectively. While folks between the ages of 60 and 64, and particularly men in that age group, were at most risk overall for any kind of hernia surgery, women were more prone to repairs of femoral hernias in the upper part of the thigh, and incisional hernias, a common side effect of abdominal surgery, the researchers found. Still, when it came to surgery for abdominal hernias across all age groups, men were at much higher risk, although women between the childbearing ages of 20 and 39 were more likely than men in their age group to have an epigastric hernia operation (performed between the sternum and belly button). The findings were published recently in the Critical Public Health journal. Gillam noted that despite high annual rates of hernia surgery worldwide, few studies have tried to break those numbers down by age and gender. Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.

SAN DIEGO, May 21, 2024 /PRNewswire/ -- Cali Biosciences Co., Ltd. (hereinafter referred to as "Cali Biosciences"), a biotechnology company dedicated to the research and development of innovative drugs, announced publication of "CPL‑01, an investigational long‑acting ropivacaine, demonstrates safety and efficacy in open inguinal hernia repair" in the scientific journal Hernia. The article's authors are Hanghang Tommy Xu, John Zimmerman, Todd Bertoch, Lee Chen, PJ Chen, and Erol Onel. "Recognition of the importance of these results by an esteemed journal such as Hernia is an important moment for Cali Biosciences," commented lead author, Dr. Tommy Xu. "In this study, our investigational drug CPL-01 out-performed not only placebo, but also standard of care Naropin®, with a clinically meaningful decrease in pain over 72 hours despite using half the opioids." Dr. Erol Onel, the Chief Medical Officer of Cali Biosciences US, LLC, agreed: "While there are several long-acting local anesthetics based on bupivacaine currently available, CPL-01 is based on ropivacaine, which is believed to be safer." The study's lead PI, Dr. Todd Bertoch, reiterated the safety of CPL-01, recounting the lack of serious adverse events in the dose advanced to Phase 3 and agreeing that "the advantages of a more effective and safer long-acting local anesthetic are obvious, and the ability to keep patients out of severe pain and towards an opioid-free recovery benefits society, the hospital systems, and of course the patients themselves." PJ Chen, the CEO of Cali Biosciences, emphasized that "along with our soon-to-be published successful Phase 2 bunion study, these results are incredibly encouraging and we are hopeful that our Phase 3 results will be as successful, leading to positive news from the regulatory authorities. When combined with our other pipeline products in the peri-operative space, Cali Biosciences is positioned to be a leader in this area with a suite of products that could help serve doctors and patients around the world." The publication may be accessed here: CPL-01, an investigational long-acting ropivacaine, demonstrates safety and efficacy in open inguinal hernia repair | Hernia (springer.com). About CPL-01 CPL-01 is a sustained-release injectable formulation of Naropin® (ropivacaine hydrochloride). Ropivacaine is a member of the amide class of local anesthetics indicated for the production of local or regional anesthesia for surgery and acute pain management. Naropin® injection is approved for local or regional anesthesia for surgery and for acute pain management. However, because of the short duration of effect of the traditional Naropin®, infusion by catheter is required if protracted local analgesia is needed for postoperative pain management. Based on the formulation of Naropin®, Cali Biosciences has applied PG-Depot, a versatile drug delivery platform, in developing CPL-01 to prolong the duration of analgesic effect at local site after a single local administration. About Cali Biosciences Cali Biosciences Co., Ltd. was established in Cayman Islands in 2021. Cali Biosciences US, LLC was established in San Diego in 2016, and later Cali Biosciences built its global headquarter in Shenzhen. Cali Biosciences is a biotechnology company dedicated to the research and development of pain management drug candidates based on its drug delivery platforms and other patented technologies, with a view to extending the coverage to manufacturing and commercialization of the pharmaceutical products it develops. The product pipeline of Cali Biosciences currently focuses on non-opioid post-operative pain management including analgesia, anesthesia, sedation, and control of inflammation. Cali Biosciences is committed to responding to unmet medical needs and serving patients and medical professionals around the world. SOURCE Cali Biosciences

The Pennsylvania-based company has specifically designed the investigational robotic-compatible OviTex IHR for use in laparoscopic and inguinal hernia repair TELA Bio announces commercial launch of OviTex IHR in the US. (Credit: Piron Guillaume on Unsplash) TELA Bio, a medical technology company delivering soft-tissue reconstruction solutions, has commercially launched the OviTex Inguinal Hernia Repair (IHR) Reinforced Tissue Matrix in the US. The Pennsylvania-based firm has specifically designed the robotic-compatible OviTex IHR surgical mesh for use in laparoscopic and inguinal hernia repair. The reinforced tissue matrix is offered in three configurations to give surgeons a range of alternatives to address specific patient, technique, or procedure-related aspects. It comes in a three- or four-layer anatomically shaped device, or a three-layer rectangular device. The medical technology company said that the trocar-compatibility of each configuration has been engineered to improve the usage of the devices in robotic and laparoscopic procedures. OviTex IHR expands upon the OviTex portfolio, a next-generation reinforced biologic that reduces the permanent polymer footprint. The OviTex range is made using layers of ovine (sheep) rumen interlaced with a little amount of polymer suture for extra strength. TELA Bio president and CEO Antony Koblish said: “OviTex IHR, designed specifically for inguinal hernia repair and robotic-compatibility usage, is the next logical addition to our growing OviTex portfolio. “The inguinal hernia market has historically been dominated by permanent synthetic mesh with few viable alternatives to address the shortcomings of those materials. “With the introduction of OviTex IHR, we are addressing this need and providing surgeons with advanced, economically effective soft-tissue reconstruction solutions that leverage the patient’s natural healing response.” Based on sales and internal data, OviTex has over eight years of clinical experience, more than 45,000 implantations, and 35 published or presented works showcasing its clinical efficacy in hernia repair, said TELA Bio. The data contains an earlier retrospective study that investigated OviTex Core Permanent in a range of hernia repair procedures and indications. The trial assessed 259 patients who had undergone robotic inguinal hernia TAPP repair utilising the ReBAR approach. The results showed an average follow-up of 1.5 years and a low recurrence rate of 1.2%. Last month, the commercial-stage medical technology firm launched the LIQUIFIX FIX8 Laparoscopic and LIQUIFIX Precision Open Hernia Mesh Fixation Devices in the US.